PT1509525E - Processo para preparação de xantinas inibidoras da fosfodiesterase v e de seus precursores - Google Patents

Processo para preparação de xantinas inibidoras da fosfodiesterase v e de seus precursores Download PDF

Info

Publication number
PT1509525E
PT1509525E PT03734281T PT03734281T PT1509525E PT 1509525 E PT1509525 E PT 1509525E PT 03734281 T PT03734281 T PT 03734281T PT 03734281 T PT03734281 T PT 03734281T PT 1509525 E PT1509525 E PT 1509525E
Authority
PT
Portugal
Prior art keywords
compound
alkyl
group
reacting
base
Prior art date
Application number
PT03734281T
Other languages
English (en)
Portuguese (pt)
Inventor
Vilas H Dahanukar
Hoa N Nguyen
Cecilia A Orr
Fucheng Zhang
Ilia A Zavialov
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PT1509525E publication Critical patent/PT1509525E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT03734281T 2002-05-31 2003-05-30 Processo para preparação de xantinas inibidoras da fosfodiesterase v e de seus precursores PT1509525E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38447802P 2002-05-31 2002-05-31

Publications (1)

Publication Number Publication Date
PT1509525E true PT1509525E (pt) 2006-12-29

Family

ID=29712039

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03734281T PT1509525E (pt) 2002-05-31 2003-05-30 Processo para preparação de xantinas inibidoras da fosfodiesterase v e de seus precursores

Country Status (17)

Country Link
US (2) US7074923B2 (US07786301-20100831-C00013.png)
EP (1) EP1509525B9 (US07786301-20100831-C00013.png)
JP (1) JP2005529934A (US07786301-20100831-C00013.png)
CN (2) CN100497336C (US07786301-20100831-C00013.png)
AR (1) AR040232A1 (US07786301-20100831-C00013.png)
AT (1) ATE336494T1 (US07786301-20100831-C00013.png)
AU (1) AU2003238822A1 (US07786301-20100831-C00013.png)
CA (1) CA2483923A1 (US07786301-20100831-C00013.png)
CY (1) CY1105774T1 (US07786301-20100831-C00013.png)
DE (1) DE60307628T2 (US07786301-20100831-C00013.png)
DK (1) DK1509525T5 (US07786301-20100831-C00013.png)
ES (1) ES2270047T3 (US07786301-20100831-C00013.png)
HK (1) HK1068139A1 (US07786301-20100831-C00013.png)
MX (1) MXPA04011862A (US07786301-20100831-C00013.png)
PT (1) PT1509525E (US07786301-20100831-C00013.png)
WO (1) WO2003101992A1 (US07786301-20100831-C00013.png)
ZA (1) ZA200408719B (US07786301-20100831-C00013.png)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
TW200404802A (en) * 2002-05-31 2004-04-01 Schering Corp Xanthine phosphodiesterase V inhibitor polymorphs
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
CA2533715A1 (en) 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
AR047948A1 (es) * 2003-11-21 2006-03-15 Schering Corp Formulaciuones de inhibidores de la fosfodiesterasa v
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) * 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2057160A1 (en) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EA031225B1 (ru) * 2008-08-15 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы дпп-4 для заживления ран
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) * 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
JPH0372480A (ja) * 1989-08-10 1991-03-27 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びそれらを有効成分とする気管支拡張剤
CA2030112A1 (en) * 1989-11-24 1991-05-25 Yasuo Ito Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
JPH04128285A (ja) * 1990-06-27 1992-04-28 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH04279586A (ja) * 1991-03-05 1992-10-05 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH051065A (ja) * 1991-06-20 1993-01-08 Hokuriku Seiyaku Co Ltd キサンチン誘導体
DE59208572D1 (de) * 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
DE4411660A1 (de) * 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
ATE226583T1 (de) * 1996-06-07 2002-11-15 Hoechst Ag Verwendung von theophyllinderivaten zur behandlung und propylaxe von schockzuständen, neue xanthinverbindungen und verfahren zu deren herstellung
HUP0301622A3 (en) * 2000-07-04 2006-05-29 Novo Nordisk As Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1421084B1 (en) 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
EP1463727A2 (en) * 2001-09-19 2004-10-06 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
EP1442042A1 (en) 2001-11-09 2004-08-04 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
ATE409466T1 (de) * 2002-01-11 2008-10-15 Novo Nordisk As Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
JP2004043429A (ja) * 2002-02-25 2004-02-12 Eisai Co Ltd 新規キサンチン誘導体およびｄｐｐｉｖ阻害剤
TW200404802A (en) * 2002-05-31 2004-04-01 Schering Corp Xanthine phosphodiesterase V inhibitor polymorphs
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
KR101150449B1 (ko) * 2002-08-21 2012-06-01 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 8-［3-아미노-피페리딘-1-일］-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물
AU2003269850A1 (en) * 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
AU2003280680A1 (en) * 2002-11-01 2004-06-18 Sumitomo Pharmaceuticals Co., Ltd. Xanthine compound
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
CA2533715A1 (en) * 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
US7074923B2 (en) 2006-07-11
CN100497336C (zh) 2009-06-10
CN1668618A (zh) 2005-09-14
DE60307628D1 (de) 2006-09-28
US20030232987A1 (en) 2003-12-18
CN101538224A (zh) 2009-09-23
WO2003101992A1 (en) 2003-12-11
EP1509525B1 (en) 2006-08-16
DK1509525T5 (da) 2007-07-30
AR040232A1 (es) 2005-03-23
EP1509525B9 (en) 2007-10-31
HK1068139A1 (en) 2005-04-22
JP2005529934A (ja) 2005-10-06
MXPA04011862A (es) 2005-03-31
ZA200408719B (en) 2005-11-15
CY1105774T1 (el) 2011-02-02
CA2483923A1 (en) 2003-12-11
EP1509525A1 (en) 2005-03-02
ES2270047T3 (es) 2007-04-01
DK1509525T3 (da) 2006-12-11
DE60307628T2 (de) 2007-08-09
US20060205943A1 (en) 2006-09-14
ATE336494T1 (de) 2006-09-15
US7786301B2 (en) 2010-08-31
AU2003238822A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
PT1509525E (pt) Processo para preparação de xantinas inibidoras da fosfodiesterase v e de seus precursores
ES2789798T3 (es) Procedimiento para la preparación de intermedios de N-[3-(aminometil)oxetan-3-il]carbamato
EP0373998B1 (fr) Ethers d'oxime de propénone, procédé pour leur préparation et compositions pharmaceutiques les contenant
CA2031328A1 (en) Xanthine derivatives, their production and use
JP6374436B2 (ja) 純粋なエルロチニブ
US20120035192A1 (en) Selective antagonists of a2a adenosine receptors
CZ284256B6 (cs) Nový způsob výroby formoterolu a příbuzných sloučenin
CA1044241A (en) Imidazoline derivatives and the preparation thereof
FR2619818A1 (fr) Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
EP2170840A1 (en) An improved process for preparing purine derivative
KR920002295B1 (ko) 프롤리디논 유도체의 제조방법
CA1291125C (en) Pyrimidine derivatives
WO2000024742A1 (en) Pyrazolopyridine as adenosine antagonists
KR950014792B1 (ko) 벤즈이미다졸 유도체 및 이의 제조방법
FI65996C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara n-2-furylmetyl)-5-sulfamoyl-ortanilsyror och deras salter
JPS6191172A (ja) ２‐ピリジン‐チオール誘導体、その製造方法およびそれを含有する医薬組成物
EP1719772A1 (en) Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
EP0136198A1 (fr) Dérivés de triazolo pyrimidine, leur procédé de préparation et leur application thérapeutique en tant que toni-cardiaques
BE897358A (fr) Derives amines de benzylidene-pyrrolo [2,1-b] quinazolines et de benzylidene-pyrido [2,1-b] quinazolines
HU198179B (en) Process for producing n-methyl-1-alkylthio-2-nitroethenamine derivatives
SU1250170A3 (ru) Способ получени дихлоргидрата пирбутерола
WO1998015524A1 (en) Improved process for the synthesis of beta-ketonitriles
HU204771B (en) Process for producing anilinofumarates from chloromaleates or chlorofumarates or from their mixture
HRP20000095A2 (en) Preparation process of pure atenolol enantiomer
JPS5833872B2 (ja) ヘキサヒドロジベンゾフラン −３− オンノシンキナユウドウタイオヨビ ソノエンルイノセイゾウホウ